

## DAFTAR PUSTAKA

- Alarfaj, A.S. and Khalil, N. (2014) 'Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia', *Clinical Rheumatology*, 33(12), pp. 1731–1736. doi:10.1007/s10067-014-2686-z.
- Amissah-Arthur MB, Gordon C (2010) Contemporary treatment of systemic lupus erythematosus: an update for clinicians. *Ther Adv Chronic Dis* 1:163–175. <https://doi.org/10.1177/204062231038010>.
- Anwar, R. (2015) 'SINTESIS, FUNGSI DAN INTERPRETASI PEMERIKSAAN HORMON REPRODUKSI', *Repository Fakultas Kedokteran Universitas Padjajaran*, pp. 1–31.
- Arief, A.R. (2015) 'Nefritis Lupus', *Medula Unila*, 4(2), pp. 13–16.
- Arnaud, L. *et al.* (2017) 'Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis', *Arthritis & Rheumatology*, 69(6), pp. 1272–1279. doi:10.1002/art.40057.
- A. Groehler, P. W. Villalta, C. Campbell, and N. Tretyakova, "Covalent DNA-protein cross-linking by phosphoramidate mustard and nornitrogen mustard in human cells," *Chemical Research in Toxicology*, vol. 29, no. 2, pp. 190–202, 2016.
- BC Renal GN Committee (2019) 'Gonadal Toxicity with Cyclophosphamide', *Provincial Standards & Guidelines*, pp. 1–19.
- Bernier MO, Mikaeloff Y, Hudson M, Suissa S. Combined oral contraceptive use and the risk of systemic lupus erythematosus. *Arthritis Rheum.* (2009) 61:476–81. doi: 10.1002/art.24398.
- Blumenfeld Z. Fertility preservation and GnRH agonists in chemotherapy. *Ann Oncol.* 2011;22(9):1924–35. doi:10.1093/annonc/mdq660.
- Bondy, C. A. (2007). "Care of Girls and Women with Turner Syndrome: A Clinical Practice Guideline." *Journal of Clinical Endocrinology & Metabolism*, 92(1), 10-25.
- Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. *Ann Intern Med.* 1993;119(5):366-369.
- Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. *Endocr Rev.* 2009;30(5):465–93. doi:10.1210/er.2009-0006.
- Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. *Ann Intern Med.* (2005) 142:953–62. doi: 10.7326/0003-4819-142-12\_Part\_1-200506210-00004.

- Ceccarelli F, Orefice V, Perrone G, Pirone C, Perricone C, Truglia S, et al. Premature ovarian failure in patients affected by systemic lupus erythematosus: a cross-sectional study. *Clin Exp Rheumatol.* (2020) 38:450–4.
- Cedars, M.I. (2022) ‘Evaluation of Female Fertility—AMH and Ovarian Reserve Testing’, *The Journal of Clinical Endocrinology & Metabolism*, 107(6), pp. 1510–1519. doi:10.1210/clinem/dgac039.
- Chen CH, Lin KC, Lin SJ, et al. Low body mass index is associated with risk of premature ovarian insufficiency: a nationwide population-based study. *BJOG.* 2021;128(3):560–8. doi:10.1111/1471-0528.16446.
- Christou EAA, Banos A, Kosmara D, Bertias GK, Boumpas DT. Sexual dimorphism in SLE: above and beyond sex hormones. *Lupus.* (2019) 28:3–10. doi:10.1177/0961203318815768.
- Clowse, M.E.B. *et al.* (2011) ‘Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener’s)’, *Arthritis Care & Research*, 63(12), pp. 1777–1781. doi:10.1002/acr.20605.
- Costedoat-Chalumeau N, Galicier L, Aumaitre O et al (2013) Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). *Ann Rheum Dis* 72:1786–1792. <https://doi.org/10.1136/annrheumdis-2012-202322>.
- Davey RA, Grossmann M. Androgen receptor structure, function and biology: from bench to bedside. *Clin Biochem Rev.* (2016) 37:3–15.
- Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. *Lancet.* 2019;393(10188):2344–58
- E. C. Somers, W. Marder, G. M. Christman, V. Ognenovski, and W. J. McCune, “Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus,” *Arthritis and Rheumatism*, vol. 52, no. 9, pp. 2761–2767, 2005.
- El-Serafi I, Terelius Y, Gréen H, Ehrsson H, Hassan M. Cyclophosphamide pharmacokinetics and metabolism in humans: the role of cytochrome P450 enzymes. *Curr Drug Metab.* 2015;16(8):701–10.
- Eklom-Kullberg S, Kautiainen H, Alha P, Helve T, Leirisalo-Repo M, Julkunen H. Reproductive health in women with systemic lupus erythematosus compared to population controls. *Scand J Rheumatol.* (2009) 38:375–80. doi: 10.1080/03009740902763099.
- Elbakry, S.A. *et al.* (2020) ‘Impact of cyclophosphamide on gonadotropins in menopausal systemic lupus erythematosus patients: Relation to disease activity and damage’, *The Egyptian Rheumatologist*, 42(3), pp. 207–211. doi:10.1016/j.ejr.2020.06.001.
- Fanouriakis, A. *et al.* (2021) ‘Update on the diagnosis and management of systemic lupus erythematosus’, *Ann Rheum Dis*, 80, pp. 14–25.

doi:10.1136/annrheumdis-2020-218272.

- Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Arnaud L, et al. 2024 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis.* 2024;83(1):15-29.
- Fatmawati, A. (2018) 'Regulasi Diri pada Penyakit Kronis-Systemic Lupus Erythematosus: Kajian Literatur', *Jurnal Keperawatan Indonesia*, 21(1), pp. 43–50.
- Fatoye F, Gebrye T, Mbada C. (2022) 'Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis', *Rheumatology International*, 42(12), pp. 2097–2107. doi:10.1007/s00296-022-05183-4.
- Giani, M.T. and Septian, M.R. (2022) 'Diagnosis dan Tata Laksana Nefritis Lupus', *Cermin dunia kedokteran*, 49(12), pp. 671–676.
- Gravholt, C. H., Andersen, N. H., Conway, G. S., et al. (2017). "Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: 2016 Update." *European Journal of Endocrinology*, 177(3), G1-G70.
- Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. *J Clin Invest.* (2002) 109:1625–33. doi: 10.1172/JCI0214873.
- Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. *Arthritis Rheum.* 2002;46(8):2121–31. doi:10.1002/art.10461.
- Hermartin, D. and Siregar, N.A. (2021) 'Faktor-faktor yang mempengaruhi infertilitas primer pada masa reproduksi di rsud gunung tua', *Jurnal Sains Riset (JSR)*, 11(2), pp. 469–475. doi:10.47647/jsr.v10i12.
- Inui H, Ogasawara T, Naito, Sekigawa I, Takasaki Y, Hayashida Y, Takamori K, et al. Estrogen receptor expression by peripheral blood mononuclear cells of patients with systemic lupus erythematosus. *Clin Rheumatol.* (2007) 26:1675–8. doi: 10.1007/s10067-007-0568-3.
- I. Park, S. Lee, K. J. Ryu *et al.*, "A gonadotropin-releasing hormone agonist for the prevention of docetaxel-induced gonadal damage," *Journal of Obstetrics and Gynaecology*, vol. 37, no. 6, pp. 783–789, 2017.
- Jeelani R, Bluth MH. Reproductive function and pregnancy. In: McPherson RA, Pincus MR, eds. *Henry's Clinical Diagnosis and Management by Laboratory Methods*. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 26.
- Jha, S.B. *et al.* (2022) 'Systemic Lupus Erythematosus and Cardiovascular Disease', *Cureus*, 14(2). doi:10.7759/cureus.22027.
- Jia WY, Zhang JJ (2022) Effects of glucocorticoids on leukocytes: genomic and non-genomic mechanisms. *World J Clin Cases* 10:7187–7194. <https://doi.org/10.12998/wjcc.v10.i21.7187>.
- Justiz, V.A., Goyal, A. and Varacallo, M. (2022) 'Systemic Lupus Erythematosus',

*StatPearls*, pp. 1–32.

- Kanno, T.Y.N. *et al.* (2019) ‘Toxic effects of different doses of cyclophosphamide on the reproductive parameters of male mice’, *Brazilian Journal of Pharmaceutical Sciences*, 45(2), pp. 313–319. doi:10.1590/S1984-82502009000200017.
- Kataryzna P.B., Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus : a clinician’s perspective. *Rheumatology International* (2023) 43:1395–1407. doi :10.1007/s00296-023-05306-5.
- Kim JW, Jung JY, Kim HA, Yang JI, Kwak DW, Suh CH. Lupus low disease activity state achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus. *J Rheumatol.* (2021) 48:707–16. doi: 10.3899/jrheum.200802.
- Kiriakidou M, Ching CL. Systemic lupus erythematosus. *Ann Intern Med.* (2020) 172:Itc81–96. doi: 10.7326/AITC202006020.
- Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol.* (2016) 16:626–38. doi: 10.1038/nri.2016.90.
- K. Takada, G. G. Illei, and D. T. Boumpas, “Cyclophosphamide for the treatment of systemic lupus erythematosus,” *Lupus*, vol. 10, no. 3, pp. 154–161, 2001.
- Lazarus, J. H., & Scher, J. (2004). "Thyroid Hormones and the Pituitary Gonadotropins." *Endocrinology and Metabolism Clinics of North America*, 33(2), 261-272.
- Loucks AB. Energy balance and body composition in sports and exercise. *J Sports Sci.* 2004;22(1):1–14. doi:10.1080/0264041031000140518.
- Lucic, A.T. (2022) ‘Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Diagnosis and Treatment Approach’, *Serbian Journal of Experimental and Clinical Research*, 23(4), pp. 361–367. doi:10.2478/sjecr-2017-0071.
- Mayorga J, Alpízar-Rodríguez D, Prieto-Padilla J, Romero-Díaz J, Cravioto MC. Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. *Lupus.* (2016) 25:675–83. doi: 10.1177/0961203315622824.
- Ma, W. *et al.* (2013) ‘Subclinical Impairment of Ovarian Reserve in Systemic Lupus Erythematosus Patients with Normal Menstruation Not Using Alkylating Therapy’, *Journal of Women’s Health*, 22(12), pp. 1023–1027. doi:10.1089/jwh.2013.4255.
- M. A. Dooley and R. Nair, “Therapy insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease,” *Nature Clinical Practice. Rheumatology*, vol. 4, no. 5, pp. 250–257, 2008.
- Medeiros PB, Febronio MV, Bonfa E, Borba EF, Takiuti AD, Silva CA. Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. *Lupus.* (2009) 18:38–43. doi: 10.1177/0961203308094652.

- Medeiros MM, Silveira VA, Menezes AP. Risk factors for ovarian failure in patients with systemic lupus erythematosus. *Clin Exp Rheumatol.* 2001;19(6):725-9.
- Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. *Hum Reprod Update.* 2001;7(6):535-43. doi:10.1093/humupd/7.6.535.
- Melmed, S., Polonsky, K. S., Larsen, P. R., & Kronenberg, H. M. (2016). *Williams Textbook of Endocrinology*. 13th Edition. Elsevier. 1888. doi: 10.4183/aeb.2016.113.
- Miao, X., Liu, X., & Li, T. (2020). "Obesity and Its Impact on the Reproductive Hormones and FSH Levels in Women." *Obesity Reviews*, 21(7), e13072.
- Mok CC, Lau CS, Ho CT, Wong RW. Do flares of systemic lupus erythematosus decline after menopause? *Scand J Rheumatol.* (1999) 28:357-62. doi: 10.1080/03009749950155346.
- Mok CC, Ho CTK, Chan KW, Lau CS, Wong RWS. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. *Arthritis Rheum* 2002;46:1003-13.
- Muthusamy, K., & Neff, J. (2017). "Effects of Alcohol on Reproductive Hormones: A Review." *Alcohol and Alcoholism*, 52(6), 646-652.
- Naser, A.M. *et al.* (2023) 'Diagnosis of Infertility: What Is New?: Review Article', *The Egyptian Journal of Hospital Medicine*, 91, pp. 4487-4491.
- Nurlita, D. *et al.* (2019) 'Neurospikiatrik Sistemik Lupus Eritematosus', *Medula*, 8(2), pp. 59-64.
- Ogino, M.H. and Tadi, P. (2023) 'Cyclophosphamide', *Encyclopedia of Toxicology: Third Edition*, pp. 1111-1113. doi:10.1016/B978-0-12-386454-3.00720-X.
- Orlowski, M. and Sarao, M.S. (2023) 'Physiology, Follicle Stimulating Hormone', *StatPearls* [Preprint].
- Ortona E, Pierdominici M, Maselli A, Veroni C, Aloisi F, Shoenfeld Y. Sex- based differences in autoimmune diseases. *Ann Ist Super Sanita.* (2016) 52:205-12.
- Perhimpunan Reumatologi Indonesia (2019) *Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik*. Jakarta: Perhimpunan Reumatologi Indonesia.
- Petri, M. (2004) 'Cyclophosphamide: new approaches for systemic lupus erythematosus', *Lupus*, 13(5), pp. 366-371. doi:10.1191/0961203303lu1028oa.
- Petri M. Sex hormones and systemic lupus erythematosus. *Lupus.* (2008) 17:412-5. doi: 10.1177/0961203308090026.
- Porta S, Danza A, Arias Saavedra M et al (2020) Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. *J Clin Med* 9:2709. <https://doi.org/10.3390/jcm9092709>.

- Pouresmaeili F, Fazeli Z. Premature ovarian failure: *a critical condition in the reproductive potential with various genetic causes*. *Int J Fertil Steril*. 2014 Apr;8(1):1-12. [[PMC free article](#)] [[PubMed](#)]
- Rezzani, R. *et al.* (2020) ‘Thymus-Pineal Gland Axis: Revisiting Its Role in Human Life and Ageing’, *International Journal of Molecular Sciences*, 21(22), p. 8806. doi:10.3390/ijms21228806.
- Rider V, Jones SR, Evans M, Abdou NI. Molecular mechanisms involved in the estrogen-dependent regulation of calcineurin in systemic lupus erythematosus T cells. *Clin Immunol*. (2000) 95:124–34. doi: 10.1006/clim.2000.4844.
- Rider V, Jones S, Evans M, Bassiri H, Afsar Z, Abdou NI. Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. *J Rheumatol*. (2001) 28:2644–9.
- Rojas-Rivera, J.E. *et al.* (2023) ‘Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)’, *Clinical Kidney Journal*, 16(9), pp. 1384–1402. doi:10.1093/ckj/sfad055.
- Sada K, Matsuda M, Kuwana M. The impact of cyclophosphamide administration on ovarian reserve in women with connective tissue diseases. *Mol Reprod Dev*. 2025;35(1):88-97.
- Sarwar, S. *et al.* (2021) ‘Neuropsychiatric Systemic Lupus Erythematosus: A 2021 Update on Diagnosis, Management, and Current Challenges’, *Cureus*, 13(9). doi:10.7759/cureus.17969.
- Shaikh, M.F., Jordan, N. and Cruz, D.P.D. (2017) ‘Systemic lupus erythematosus’, *Clinical Medicine*, 17(1), pp. 78–83.
- Sharma SK, Dhir V, Suryanarayana BS, Singh S, Sharma A. Ovarian dysfunction with monthly intravenous cyclophosphamide (modified NIH regimen) in young women with lupus nephritis. *Arthritis Res Ther*. 2020;22(1):96.
- Silva CA, Brunner HI. Gonadal functioning and preservation of reproductive fitness in juvenile systemic lupus erythematosus. *Lupus*. 2007;16(8):593-9
- Silva C, Yamada H, Savani BN. Ovarian failure after chemotherapy: diagnosis and management. *Oncol Hematol Rev*. 2015;11(2):93–9. doi:10.17925/OHR.2015.11.02.93.
- Singh RP, Bischoff DS. Sex hormones and gender influence the expression of markers of regulatory T Cells in SLE patients. *Front Immunol*. (2021) 12:619268. doi: 10.3389/fimmu.2021.619268.
- Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. *Arthritis Rheum*. 2005;52(9):2761–2767. doi:10.1002/art.21247.
- Stamm B, Barbhaiya M, Siegel C, Lieber S, Lockshin M, Sammaritano L. Infertility in systemic lupus erythematosus: what rheumatologists need to know in a new

- age of assisted reproductive technology, *Lupus Science & Medicine*, 2022;9:e000840. doi:10.1136/ lupus-2022-000840.
- Tanzilia, M.F., Tambunan, B.A. and Dewi, D.N.S.S. (2021) 'Tinjauan Pustaka : Patogenesis dan Diagnosis Sistemik Lupus Eritematosus', *Syifa' Medika*, 11(2), pp. 139–164.
- Thomas, P. G., & Bailey, J. L. (2012). "Impact of Smoking on Hormonal Regulation and Reproductive Function." *Clinical Endocrinology*, 76(5), 740-749.
- Tunnicliffe DJ, Palmer SC, Henderson L *et al.* (2018) Immuno- suppressive treatment for proliferative lupus nephritis. *Cochrane Database Syst Rev* 6:CD002922. <https://doi.org/10.1002/14651858.CD002922.pub4>.
- Vander Borcht, M. and Wyns, C. (2018) 'Fertility and infertility: Definition and epidemiology', *Clinical Biochemistry*, 62, pp. 2–10. doi:10.1016/j.clinbiochem.2018.03.012.
- Wang S, Zhang Y, Mensah V, Huber W J 3<sup>rd</sup>, Huang Y T, Alvero R. *Discordant anti-müllerian hormone (AMH) and Follicle stimulating hormone (FSH) among women undergoing in vitro fertilization (IVF): which one is the better predictor for live birth? J Ovarian Res.* 2018 Jul 16;11(1):60. Doi: 10.1186/s13048-0180430-z. PMID: 30012195; PMCID: PMC6048693.
- Wulandari, E. (2018) 'Hormon Hipotalamus Dan Hipofisis', *Repository UIN Syarif Hidayatullah*, pp. 20–60.
- Xu M, Tian LL, Li XL, Bao C, Zhang HW, Chen HW. Ovarian function in patients with systemic lupus erythematosus: Pathogenesis, drug application and prospective therapies. *World J Exp Med.* 2024 Jun 20;14(2):88867. doi: 10.5493/wjem.v14.i2.88867.
- Yap DY, Lee P, Tam C *et al.* (2018) B cell subsets and signatures in lupus nephritis patients receiving mycophenolate or azathioprine maintenance. *J Am Soc Nephrol* 29:336. <https://doi.org/10.3389/fimmu.2020.01732>
- Yuliana, M. and Wibowo, W.A. (2020) 'Sistemik Lupus Eritematosus : Laporan Kasus', *Repository FK Universitas Muhammadiyah Surakarta*, pp. 294–307.
- Yulianti, R. *et al.* (2020) 'EFEK PROTEKTIF ZINK TERHADAP STRES OKSIDATIF TESTIS DAN KUALITAS SPERMA PADA MENCIT JANTAN (Mus musculus) SETELAH DIINDUKSI CYCLOPHOSPHAMIDE', *Jurnal Biosains Pascasarjana*, 22(2), pp. 63–72.
- Yuliasih (2020) *Perkembangan Patogenesis dan Tatalaksana Systemic Lupus Erythematosus*.
- Zhang, S. (2021) 'Efficacy of cyclophosphamide plus prednisone for patients with systemic lupus erythematosus and the effects on immune function', *Int J Clin Exp Med*, 14(2), pp. 1242–1249.